Evaluating Pirfenidone’s Potential in Treating Patients with Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD)

Paper Summary

Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) is a serious complication with few effective treatment options. This study reviews the potential of pirfenidone as a treatment for SSc-ILD by analyzing multiple case studies. The findings suggest that pirfenidone may improve lung function, including vital capacity and the lungs’ ability to transfer oxygen, and enhance patients’ quality of life. However, responses varied between patients, particularly concerning dosage, indicating a need for more research. The safety profile of pirfenidone appears favorable, consistent with earlier clinical trials. Despite these promising results, its use remains limited due to a lack of large-scale studies, regulatory challenges, and competition from other drugs. The paper recommends future well-designed randomized controlled trials to determine optimal dosing and explore combination therapies. Such research could help broaden treatment options and provide clearer guidance for managing this difficult condition.